IMTX vs. MESO, RLAY, RGNX, CRGX, AUTL, BCRX, HLVX, PRME, NVAX, and SRRK
Should you be buying Immatics stock or one of its competitors? The main competitors of Immatics include Mesoblast (MESO), Relay Therapeutics (RLAY), REGENXBIO (RGNX), CARGO Therapeutics (CRGX), Autolus Therapeutics (AUTL), BioCryst Pharmaceuticals (BCRX), HilleVax (HLVX), Prime Medicine (PRME), Novavax (NVAX), and Scholar Rock (SRRK). These companies are all part of the "biological products, except diagnostic" industry.
Mesoblast (NASDAQ:MESO) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability.
Mesoblast has a net margin of 0.00% compared to Mesoblast's net margin of -107.80%. Immatics' return on equity of 0.00% beat Mesoblast's return on equity.
Mesoblast currently has a consensus price target of $13.67, suggesting a potential upside of 85.94%. Immatics has a consensus price target of $16.00, suggesting a potential upside of 45.99%. Given Immatics' higher possible upside, analysts clearly believe Mesoblast is more favorable than Immatics.
In the previous week, Immatics had 13 more articles in the media than Mesoblast. MarketBeat recorded 17 mentions for Immatics and 4 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.82 beat Immatics' score of 0.35 indicating that Immatics is being referred to more favorably in the news media.
1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Comparatively, 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Mesoblast received 377 more outperform votes than Immatics when rated by MarketBeat users. However, 72.22% of users gave Immatics an outperform vote while only 70.45% of users gave Mesoblast an outperform vote.
Mesoblast has a beta of 3.45, indicating that its share price is 245% more volatile than the S&P 500. Comparatively, Immatics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.
Mesoblast has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than Mesoblast, indicating that it is currently the more affordable of the two stocks.
Summary
Mesoblast beats Immatics on 10 of the 17 factors compared between the two stocks.
Get Immatics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immatics Competitors List
Related Companies and Tools
